df-2156

Ladarixin Sodium, an Chemokine CXCR antagonist, is used potentially for the treatment of type I diabetes.

Ladarixin (DF 2156A free base) is an orally active, non-competitive CXCR1/CXCR2 allosteric inhibitor that suppresses AKT, NF-κB, and angiogenesis, thereby slowing the progression of experimental human melanoma. It may be employed in research concerning COPD, asthma, and melanoma.